Literature DB >> 21677004

Bone health in adult men and women with a history of juvenile idiopathic arthritis.

Judith Thornton1, Stephen R Pye, Terence W O'Neill, David Rawlings, Roger M Francis, Deborah P M Symmons, Darren M Ashcroft, Helen E Foster.   

Abstract

OBJECTIVE: Our aim was to determine areal bone mineral density (BMD(a)) and disease-related factors linked with BMD(a) in adults with a history of juvenile idiopathic arthritis (JIA).
METHODS: Men and women with a history of JIA attending a young adult rheumatology clinic in Newcastle, UK, underwent dual energy x-ray absorptiometry (DEXA) of the lumbar spine and total hip. Information was obtained about disease duration and subtype, previous treatment including corticosteroid and methotrexate therapy, and large-joint replacement. Subjects completed the modified Health Assessment Questionnaire (HAQ). Blood was taken for assessment of C-reactive protein, erythrocyte sedimentation rate, and rheumatoid factor (RF).
RESULTS: Seventy-one women and 16 men, mean age 28.7 and 31.4 years, and mean disease duration 20.6 and 24.0 years, respectively, were studied. Mean BMD(a) was 0.982 (Z-score = -0.328; 95% CI -0.657, 0.001) and 1.028 g/cm(2) (Z-score = -0.251; 95% CI -1.266, 0.764) in women and men, respectively, at the spine and 0.817 (Z-score = -0.542; 95% CI -0.975, -0.109) and 0.857 g/cm(2) (Z-score = -0.176; 95% CI -2.323, 1.971) at the hip. After adjusting for age and sex, increasing HAQ score was associated with both lower spine BMD(a) and hip BMD(a). Compared with patients with oligoarticular disease, those with enthesitis-related arthritis had higher BMD(a) at the spine, while those with extended oligoarticular and polyarticular RF-negative disease had lower hip BMD(a). Oral corticosteroids and the presence of a large-joint replacement were associated with lower BMD(a) at both the spine and hip.
CONCLUSION: There was a trend toward low BMD(a) in women with a history of JIA. These patients may be at risk of the complications of osteoporosis including fragility fractures and should be considered for targeted preventive measures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677004     DOI: 10.3899/jrheum.101232

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 2.  Causes, mechanisms and management of paediatric osteoporosis.

Authors:  Outi Mäkitie
Journal:  Nat Rev Rheumatol       Date:  2013-04-16       Impact factor: 20.543

3.  Tmem178 acts in a novel negative feedback loop targeting NFATc1 to regulate bone mass.

Authors:  Corinne E Decker; Zhengfeng Yang; Ryan Rimer; Kyung-Hyun Park-Min; Claudia Macaubas; Elizabeth D Mellins; Deborah V Novack; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

4.  Automated determination of bone age and bone mineral density in patients with juvenile idiopathic arthritis: a feasibility study.

Authors:  Janneke Anink; Charlotte M Nusman; Lisette W A van Suijlekom-Smit; Rick R van Rijn; Mario Maas; Marion A J van Rossum
Journal:  Arthritis Res Ther       Date:  2014-08-27       Impact factor: 5.156

5.  Joint cartilage thickness and automated determination of bone age and bone health in juvenile idiopathic arthritis.

Authors:  Marinka Twilt; Dan Pradsgaard; Anne Helene Spannow; Arne Horlyck; Carsten Heuck; Troels Herlin
Journal:  Pediatr Rheumatol Online J       Date:  2017-08-10       Impact factor: 3.054

6.  No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis.

Authors:  P C E Hissink Muller; W G van Braak; D Schreurs; C M Nusman; S A Bergstra; R Hemke; D Schonenberg-Meinema; J M van den Berg; T W Kuijpers; Y Koopman-Keemink; M A J van Rossum; L W A van Suijlekom-Smit; D M C Brinkman; C F Allaart; R Ten Cate; M Maas
Journal:  Pediatr Rheumatol Online J       Date:  2019-09-04       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.